# A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Source: https://onco.cc/trials/nct04550104/  
OnCo record `nct04550104` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT04550104 as recruiting, last updated 2025-12-19. Enrolment is 200 planned participants, an estimate. Interventions: Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD1390, Ceralasertib, AZD5305, Durvalumab. Primary measures include Dose limiting Toxicities. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT04550104
- Phase: 1
- Setting: A Platform Study of DNA Damage Response Inhibitors in Combination With Conventional Radiotherapy in Non Small Cell Lung Cancer
- Sponsor: University of Leeds

## Sources

- ClinicalTrials.gov NCT04550104: https://clinicaltrials.gov/study/NCT04550104

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)

---
JSON: https://onco.cc/api/v1/entities/nct04550104.json